Qi Wang

Electrocatalysts for Energy Conversion (43) Advanced Photocatalysis Techniques (43) Supercapacitor Materials and Fabrication (34) Graphene research and applications (27) Advancements in Battery Materials (23)

Affiliations

Brigham Young University

US 1992 - 1992

Kunming University of Science and Technology

CN 2017 - 2017

Qingdao University

CN 2019 - 2019

Qiqihar University

CN 2025 - 2025

Hebei University of Economics and Business

CN 2015 - 2015

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Qi Wang

Publication & Citation Trends

Publications

Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. OA

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back